Cervical Cancer Screening Market Size is estimated to be valued at USD 8,152.6 Million in 2021 and is expanded to grow at a significant CAGR of 5.4% over 2022-2028. An increase in the prevalence of cervical cancer due to the surge in the global female population is a considerable factor surge the growth of the cervical cancer screening market over the forecast years. Moreover, raising awareness about the cancer diseases among the people in developed countries, the surge in demand for early-stage disease diagnosis, and favorable reimbursement policies are enhancing the market’s revenue. In addition, the increase in consumption of tobacco and alcohol among the female population, the surge in prevalence of HPV infection, increase in the incidence of unsafe sex also boost the market over the forecast timeframe. Development of newer tests to diagnose cervical cancer in a more efficient way and expansion of the business into low-income markets and high prevalence of cervical cancer countries creates some opportunities for marketers. In the cervical cancer screening market, the pap smear tests segment is estimated to lead the global cervical cancer screening market in 2022, in terms of value and volume, owing to increased government funding and insurance coverage.
Recent Market Developments:
In November 2020, Hologic, Inc. announced that its new Genius™ Digital Diagnostics System is CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.